LUMIFY Drug Patent Profile

When do Lumify patents expire, and what generic alternatives are available?

Lumify is a drug marketed by Bausch And Lomb Inc and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in sixteen countries.

The generic ingredient in LUMIFY is brimonidine tartrate. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lumify

A generic version of LUMIFY was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for LUMIFY

International Patents:	37
US Patents:	4
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	8
Patent Applications:	170
Drug Prices:	Drug price information for LUMIFY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUMIFY
DailyMed Link:	LUMIFY at DailyMed

See drug prices for LUMIFY

Recent Clinical Trials for LUMIFY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tulane University	Phase 4
Bausch & Lomb Incorporated	PHASE3
University of Louisville	Phase 4

See all LUMIFY clinical trials

Pharmacology for LUMIFY

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Paragraph IV (Patent) Challenges for LUMIFY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUMIFY	Ophthalmic Solution	brimonidine tartrate	0.025%	208144	1	2021-07-12

US Patents and Regulatory Information for LUMIFY

LUMIFY is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	8,293,742
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes	8,293,742
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	11,833,245
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	11,596,600

International Patents for LUMIFY

See the table below for patents covering LUMIFY around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2515917	BRIMONIDINE POUR BLANCHIMENT DES YEUX (BRIMONIDINE FOR EYE WHITENING)
World Intellectual Property Organization (WIPO)	2015031183
Japan	2014520068
European Patent Office	2320911	COMPOSITIONS DE VASOCONSTRICTION, ET PROCÉDÉS D'UTILISATION (VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE)

Supplementary Protection Certificates for LUMIFY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014C/042	Belgium		PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: LUMIFY

Last updated: July 27, 2025

Introduction LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) has carved a distinctive niche within the ophthalmic aesthetic treatment segment since its FDA approval in 2018. Unlike traditional medications targeting underlying health conditions, LUMIFY addresses a common aesthetic concern—red eyes—through topical application. This analysis explores the market landscape, competitive positioning, revenue streams, growth drivers, and future financial outlook of LUMIFY, emphasizing the key factors influencing its dynamics.

Market Overview and Size

The global eye care market is projected to reach approximately $48 billion by 2025 [1], with the OTC pharmaceutical segment growing at a CAGR of about 4.5%-5% over recent years. LUMIFY, marketed exclusively as an over-the-counter (OTC) drug, taps into a considerable market segment comprising consumers seeking quick, non-invasive solutions for eye redness—often linked to fatigue, allergies, or environmental factors.

In the U.S., approximately 75% of adults report experiencing eye redness regularly, with a significant subset seeking OTC remedies [2]. LUMIFY’s unique positioning as a fast-acting, non-drying treatment distinguishes it from traditional vasoconstrictor eye drops like Visine, which have faced regulatory scrutiny over rebound effects with prolonged use.

Market Dynamics

Consumer Demand & Behavior

Consumer behavior remains a primary driver of LUMIFY’s market performance. Increasing awareness of eye health, coupled with rising screen time environments driven by remote work and digital device usage, has elevated demand for quick relief products. The convenience of OTC availability and a perception of safety have bolstered consumer loyalty, translating into sustained repeat purchases.

Competitive Landscape

LUMIFY competes within a crowded OTC eye drops market staffed by brands such as Visine (by Johnson & Johnson), Clear Eyes, and Rohm & Haas. However, it has distinguished itself through:

• Unique formulation: A proprietary brimonidine tartrate that reduces eye redness without the rebound effect often associated with other vasoconstrictors.
• Brand positioning: Marketed as a cosmetic enhancement rather than a medication, appealing to consumers seeking aesthetic improvement without medical intervention.
• Regulatory advantage: Its designation as a non-prescription drug allows for broader retail distribution and consumer accessibility.

Regulatory & Safety Considerations

LUMIFY’s FDA approval under the OTC monograph process in 2018 solidified its safety profile—particularly its minimal systemic absorption and low risk of rebound redness—factors that influence its competitive edge. Ongoing post-market surveillance and formulation refinements will be crucial as competitors attempt to develop similar products or improvements.

Distribution & Retail Channels

Availability across major retail outlets—including big-box stores, drugstores, and online platforms—has expanded LUMIFY's reach. Its placement alongside daily-use eye care products and the accessibility of online purchasing enhance its market penetration. Digital marketing strategies targeting millennial and Gen Z demographics further stimulate demand.

Financial Trajectory

Revenue Generation & Growth Trends

Since launch, LUMIFY has demonstrated robust sales growth:

• Estimated $300-$350 million in U.S. retail sales in 2022 [3], reflecting high consumer uptake.
• Growth driven by repeat purchase rates above 70% and increasing market share within the OTC eye care category.

Pricing Strategy

LUMIFY commands a premium over traditional vasoconstrictor eye drops—retailing at approximately $15–$20 per 0.33 oz bottle—justified by its branding as a cosmetic eye health product and its differentiated formulation. This pricing reinforces projected margins and profitability.

Profitability & Investment

As a product launched by Bausch + Lomb (owned by Bausch Health Companies), LUMIFY benefits from established distribution infrastructure and marketing expertise. The company's investment in targeted advertising, especially digital campaigns, has driven market awareness and consumer adoption. While detailed financials remain proprietary, the product's rapid growth suggests strong profitability potential.

Innovative Pipeline & Expansion

Potential product pipeline extensions—such as formulations targeting specific demographics (e.g., aging adults) or addressing other ocular aesthetics—could diversify revenue streams. Additionally, regulatory approvals in international markets (e.g., EU, Asia) could open avenues for substantial revenue expansion.

Key Factors Influencing Future Financial Trajectory

• Market Penetration: Increasing shelf space and consumer awareness will be pivotal for sustained growth.
• Consumer Behavior Trends: Rising screen time and awareness of eye health support ongoing demand.
• Regulatory Landscape: Continued compliance and vigilance against safety concerns will maintain consumer trust.
• Competitive Innovation: Emergence of alternative formulations or rebound-free vasoconstrictors could challenge LUMIFY's dominance.
• Digital & E-Commerce Expansion: Enhancing online presence and direct-to-consumer marketing will boost accessibility and sales.

Challenges & Risks

• Market Saturation: As the OTC redness relief segment matures, incremental growth may slow.
• Regulatory Scrutiny: Adverse events or safety concerns could lead to restrictions or formulation modifications.
• Brand Loyalty: Consumer shifts toward natural or holistic remedies could impact demand.
• Pricing Pressures: Competitive responses, such as lower-priced alternatives, might compress margins.

Conclusion

LUMIFY’s market dynamics are shaped by a confluence of a sizable, demand-driven consumer base, strategic differentiation, and effective distribution. Its financial trajectory appears favorable, supported by consistent growth, premium pricing, and expanding market penetration. Sustainable success will depend on ongoing innovation, regulatory compliance, and adaptation to evolving consumer preferences.

---

Key Takeaways

• Market Positioning: LUMIFY commands a unique niche within OTC eye care, leveraging its safety profile and cosmetic branding to differentiate from competitors.
• Growth Drivers: Increasing digital device usage, consumer demand for quick aesthetic solutions, and expanded retail presence underpin ongoing sales growth.
• Revenue Outlook: With estimated sales surpassing $300 million in recent years, LUMIFY’s financial trajectory indicates strong profitability prospects within the OTC eye care market.
• Competitive Landscape: Maintaining market share requires continuous innovation and vigilance against emerging formulations and regulatory challenges.
• Strategic Expansion: International market entry and product pipeline diversification represent key opportunities for future revenue expansion.

---

FAQs

1. How does LUMIFY differ from traditional eye redness drops?
LUMIFY employs brimonidine tartrate, which reduces eye redness without causing rebound or dryness, unlike traditional vasoconstrictor drops such as Visine, which may lead to increased redness with sustained use.

2. What is the primary target demographic for LUMIFY?
LUMIFY primarily targets adult consumers seeking quick, safe cosmetic relief from eye redness, especially individuals experiencing fatigue, digital eye strain, or environmental irritants.

3. Are there any safety concerns associated with long-term use of LUMIFY?
FDA approval and post-market safety data indicate minimal systemic absorption and low risk of rebound redness with appropriate use. However, sustained long-term use should follow the product’s directions to mitigate risks.

4. What factors could impede LUMIFY’s market growth?
Potential impediments include increased regulatory scrutiny, market saturation, emergence of stronger competitors, or shifts in consumer preferences towards natural remedies.

5. Are there plans for LUMIFY to expand internationally?
While specific plans are not publicly disclosed, regulatory approval in further jurisdictions could significantly expand LUMIFY’s global footprint and revenue potential.

---

References

[1] MarketsandMarkets, “Eye Care Market by Product Type & Region,” 2022.
[2] American Optometric Association, “Digital Eye Strain and Eye Redness,” 2021.
[3] Bausch + Lomb financial disclosures, 2022.